Cabaletta Bio, Inc.

Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on discovering and developing engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a fully human CD19-CAR T therapy containing a 4-1BB co-stimulatory domain, which is being evaluated in Phase 1/2 clinical trials for multiple conditions including dermatomyositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, pemphigus vulgaris, systemic sclerosis, and generalized myasthenia gravis. The company also has DSG3-CAART, a CAAR T cell therapy in Phase 1 for mucosal pemphigus vulgaris, and MuSK-CAART, an investigational cell therapy in Phase 1 for anti-MuSK antibody positive myasthenia gravis. Cabaletta Bio collaborates with the University of Pennsylvania and the Children's Hospital of Philadelphia.

Cabaletta Bio is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol CABA. The company's financial reporting and stock trading are conducted in US Dollars (USD). As a US-based company, its shares are traded in the primary US stock exchange, providing liquidity and visibility to investors globally. The NasdaqGS is a tier of the Nasdaq Stock Market that includes companies meeting higher listing standards, reflecting Cabaletta Bio's status as a clinical-stage biotechnology firm with a focus on innovative T cell therapies for autoimmune diseases.

Cabaletta Bio operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on leveraging biological processes and cellular engineering to develop therapies for medical conditions. In particular, Cabaletta Bio specializes in engineered T cell therapies, a cutting-edge area of biotechnology that involves modifying a patient's own T cells to target and treat autoimmune diseases. The company's work is at the clinical stage, meaning its product candidates are undergoing human trials to assess safety and efficacy. This places it among other biotech firms that aim to bring novel treatments to market, with a focus on addressing unmet medical needs in autoimmune disorders.

Cabaletta Bio is headquartered in Philadelphia, Pennsylvania, United States. The company was incorporated in 2017 and was originally known as Tycho Therapeutics, Inc. before rebranding to Cabaletta Bio in August 2018. Its location in Philadelphia places it within a major biotechnology hub on the East Coast, providing access to research institutions and talent. The company's history reflects a strategic shift toward developing CAR T cell therapies for autoimmune diseases, a relatively new application of this technology which has traditionally been used in oncology. Since its founding, Cabaletta Bio has built a pipeline of product candidates targeting various autoimmune conditions, leveraging collaborations with academic institutions like the University of Pennsylvania and the Children's Hospital of Philadelphia.

Cabaletta Bio is a clinical-stage biotechnology company that does not yet have approved products or generate revenue from product sales. Its business model focuses on advancing its pipeline of engineered T cell therapies through clinical development, with the goal of obtaining regulatory approval and commercializing treatments for autoimmune diseases. The company's key product candidates include resecabtagene autoleucel (a CD19-CAR T therapy), DSG3-CAART, and MuSK-CAART, all in Phase 1 or Phase 1/2 trials. Cabaletta Bio collaborates with the University of Pennsylvania and the Children's Hospital of Philadelphia to support its research. Additionally, its portfolio includes partnerships with Nanjing IASO Biotherapeutics Co., Ltd, Oxford Biomedica, Autolus Holdings (UK) Limited, and WuXi Advanced Therapies, Inc., which likely provide manufacturing, technology, or development support. These collaborations are essential for advancing its pipeline without a marketed product.